Total Funding
63
16
Total FundingSeries A raised
Growth Score
-3 pts
Heat Score
-20 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
134325
Tollys is a biopharmaceutical company focused on innate immunity, particularly on the biology and modulation of the TLR3 receptor.
- Bettina Werle: Chief Scientific Officer
- Vincent Charlon: Chief Executive OfficerPast Role: Anergis, CEO
About the Company
Tollys is a biopharmaceutical company focused on innate immunity, particularly on the biology and modulation of the TLR3 receptor. The company is advancing TL-532, a new cancer immunotherapy to treat various types of cancer. TL-532 is a structurally defined double-stranded RNA, produced synthetically and highly specific to the TLR3 receptor.
